The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...

Negative perception of schizophrenia is still prevalent in society. However, schizophrenia is only a mental disease that ...

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

‘There are many non-hallucinogenic analogues of LSD, but the fundamental difference is that all of those compounds are very ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's ...

MERIT is one of several metacognitive psychotherapies, designed especially to meet the needs of individuals living with serious mental illnesses, including schizophrenia. It is deliverable in both ...

A new study explores how brain networks differ between patients in early and chronic stages of psychosis, shedding light on ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Mellencamp previously revealed doctors had found multiple tumors. Teddi Mellencamp is sharing a positive health update on her Stage 4 cancer diagnosis. The former "Real Housewives of Beverly Hills ...

The Positive and Negative Syndrome Scale ... target for agitation behavior and cognitive impairment in schizophrenia. To conduct a precise analysis of the relationship between agitation symptoms, ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on therapy to ...

PANSS is a clinician-administered tool used to assess schizophrenia symptoms. Approved by the ... from the outset because there had not been any positive phase 3 trial in the adjunctive ...